CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Return to article

Table 1 Fatty acid composition of Jurkat and derived hyperproliferative sublines

Data are expressed as percentage (by weight) of the total cellular fatty acids and are the mean ± SD of results obtained in three different experiments with samples analyzed in duplicate.

Fatty acid Jurkat Jurkat-ws Jurkat-hp

14:0 2.0 ± 0.1 3.2 ± 0.5 3.5 ± 0.1
14:1 1.1 ± 0.1 0.4 ± 0.1 n.d.a
16:0DMA 1.7 ± 0.2 0.7 ± 0.1 n.d.
16:0 27.2 ± 0.1 17.1 ± 0.4 25.1 ± 0.6
16:1(n-9) 3.0 ± 0.1 0.7 ± 0.1 n.d.
16:1(n-7) 2.8 ± 0.1 12.9 ± 0.8 11.6 ± 0.7
18:0 15.9 ± 1.6 8.2 ± 0.7 10.0 ± 0.5
18:1(n-9) 21.6 ± 0.1 30.7 ± 2.0 33.2 ± 0.9
18:1(n-7) 8.2 ± 0.1 19.4 ± 1.5 13.8 ± 0.7
18:2(n-6) 2.3 ± 0.5 n.d. 1.4 ± 0.1
20:1(n-9) 1.1 ± 0.1 1.2 ± 0.1 n.d.
20:1(n-7) n.d. 1.6 ± 0.1 n.d.
20:4(n-6) 7.1 ± 0.7 n.d. 1.0 ± 0.1
22:4(n-6) n.d. n.d. n.d.
22:5(n-6) n.d. n.d. n.d.
22:6(n-3) 4.7 ± 0.2 n.d. n.d.
µg FA/106 cells 7.8 ± 0.2 3.2 ± 0.3 6.6 ± 0.7
Ratio polyunsaturates: monounsaturates 0.37 0.00 0.04

a n.d., not detected, DMA, dimethyl acetal from alkenyl side chains of plasmalogens.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation